Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 12.47% and Operating profit at 16.26% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
3
With ROE of 10.79%, it has a very attractive valuation with a 1.84 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,543 Million (Mid Cap)
17.00
NA
3.83%
0.11
9.95%
1.42
Revenue and Profits:
Net Sales:
335 Million
(Quarterly Results - Mar 2026)
Net Profit:
106 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.51%
0%
-10.51%
6 Months
-11.85%
0%
-11.85%
1 Year
-13.16%
0%
-13.16%
2 Years
-30.6%
0%
-30.6%
3 Years
-47.64%
0%
-47.64%
4 Years
-27.24%
0%
-27.24%
5 Years
-40.08%
0%
-40.08%
Beijing Strong Biotechnologies, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.47%
EBIT Growth (5y)
16.26%
EBIT to Interest (avg)
15.94
Debt to EBITDA (avg)
0.67
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
0.31
Tax Ratio
14.19%
Dividend Payout Ratio
370.48%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.66%
ROE (avg)
11.92%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
1.84
EV to EBIT
15.28
EV to EBITDA
13.79
EV to Capital Employed
1.78
EV to Sales
5.36
PEG Ratio
NA
Dividend Yield
5.19%
ROCE (Latest)
11.64%
ROE (Latest)
10.79%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
334.80
343.80
-2.62%
Operating Profit (PBDIT) excl Other Income
128.20
115.60
10.90%
Interest
12.40
13.20
-6.06%
Exceptional Items
0.00
-174.80
100.00%
Consolidate Net Profit
105.60
-82.50
228.00%
Operating Profit Margin (Excl OI)
382.80%
283.70%
9.91%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -2.62% vs 0.12% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 228.00% vs -184.70% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,342.10
1,648.40
-18.58%
Operating Profit (PBDIT) excl Other Income
479.00
704.90
-32.05%
Interest
49.70
47.90
3.76%
Exceptional Items
-145.20
4.50
-3,326.67%
Consolidate Net Profit
190.50
536.80
-64.51%
Operating Profit Margin (Excl OI)
303.20%
383.90%
-8.07%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -18.58% vs -4.72% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -64.51% vs 2.82% in Dec 2024
About Beijing Strong Biotechnologies, Inc. 
Beijing Strong Biotechnologies, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






